The role of thymoquinone, a major constituent of Nigella sativa, in the treatment of inflammatory and infectious diseases

Journal article

Kaneez, Fatima-Shad, Soubra, Wissam and Cordato, Dennis John. (2021). The role of thymoquinone, a major constituent of Nigella sativa, in the treatment of inflammatory and infectious diseases. Clinical and Experimental Pharmacology & Physiology. 48(11), pp. 1445-1453.
AuthorsKaneez, Fatima-Shad, Soubra, Wissam and Cordato, Dennis John

Nigella sativa (N. sativa) is an annual flowering plant that has been used as a traditional remedy for many centuries. The seed possesses a large variety of compounds with thymoquinone (TQ) considered its major but not sole bioactive constituent. Supercritical fluid extraction, geographical location, and oxidative status of N. sativa produces the highest yield of essential oil content including TQ. Thymoquinone is lipophilic, heat and light sensitive with low oral bioavailability and rapid elimination that have significantly inhibited its pharmacological development. Novel developments in nanoparticulate-based oral administration, nasal spray and transdermal delivery may allow the clinical development of N. sativa and TQ as therapeutic agents. Animal and human studies indicate a potential role of N. sativa seed oil and TQ for a diverse range of disease processes including hypertension, dyslipidaemia, type 2 diabetes mellitus, arthritis, asthma, bacterial and viral infections, neurological and dermatological disorders, as it belongs to the group of pan-assay interference compounds. This review outlines the pharmacological properties of N. sativa and TQ and their potential wide application for a large variety of human diseases. The paper will focus on recent studies of the anti-inflammatory and antiviral properties that make N. sativa and TQ promising therapeutic agents targeting contemporary inflammatory and infectious diseases including Covid 19.

KeywordsCovid 19; oxidative stress; pan-assay interference compound; SARS-CoV- 2; supercritical fluid extraction; thymoquinone
JournalClinical and Experimental Pharmacology & Physiology
Journal citation48 (11), pp. 1445-1453
PublisherJohn Wiley & Sons Australia, Ltd
Digital Object Identifier (DOI)
Scopus EID2-s2.0-85112747568
Page range1445-1453
Publisher's version
All rights reserved
File Access Level
Output statusPublished
Publication dates
Online18 Aug 2021
Publication process dates
Accepted14 Jul 2021
Deposited24 Oct 2022
Permalink -

Restricted files

Publisher's version

  • 39
    total views
  • 0
    total downloads
  • 1
    views this month
  • 0
    downloads this month
These values are for the period from 19th October 2020, when this repository was created.

Export as